Fulgent Pharma : Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

(marketscreener.com) Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology Annual...https://www.marketscreener.com/quote/stock/FULGENT-GENETICS-INC-31452986/news/Fulgent-Announces-Upcoming-Presentation-of-Clinical-Data-for-Its-Lead-Therapeutic-Oncology-Candidate-46818204/?utm_medium=RSS&utm_content=20240524